When the FDA issues a drug warning, the first instinct is to sell first and read later. Long-term holders of Eli Lilly and Novo Nordisk who did that on Monday left money on the table.
The FDA said it is requiring GLP-1 drugs such as Eli Lilly’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy to add information to the “warnings and precautions” section of labeling about the potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION. The condition occurs when blood flow to the optic nerve is reduced, causing sudden, painless vision loss, typically in one eye, and there is currently no known treatment to reverse it.
Sobering in isolation. Decisive for investors, though, only if you read what the FDA actually found.
The Numbers Behind the Warning
Because individual clinical trials recorded few or no NAION cases, the FDA conducted a meta-analysis of 126 randomized controlled trials involving 134,253 participants. The analysis included 78,217 patients receiving GLP-1 receptor agonists and 56,036 receiving placebo or other glucose-lowering comparators. It identified 15 probable NAION events in total: 10 among GLP-1 recipients and five among comparators.
That analysis identified an incidence rate of 6.4 NAION cases per 100,000 patient-years among GLP-1 users, compared with 3.8 cases per 100,000 patient-years in comparator groups.
The FDA noted that available animal data did not identify an underlying biological mechanism, and drugmakers maintain that available studies do not prove a direct causal link between the therapies and NAION.
What the Market Said
Both stocks rose on the day the FDA announced the requirement, Monday, November 9, 2026. Novo Nordisk rose about 2% on the day, and Eli Lilly finished up about 4%.
The move was not despite the warning. It was partly because of what the warning was not.
That distinction is the crux. A boxed warning or an indication restriction would rewrite prescribing. A “warnings and precautions” addition tells physicians to have a conversation. It does not tell them to stop prescribing.
In Europe, regulators concluded in June 2025 that NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking semaglutide. The FDA action mirrors, rather than escalates, that precedent.
The Litigation Risk Is Real
Label changes have a secondary effect that investors need to watch. The update arrives as both Novo Nordisk and Eli Lilly face mounting product liability lawsuits from patients alleging they developed vision loss after using the drugs without adequate warning.
Novo Nordisk’s legal exposure here arrives on top of pipeline setbacks that have already pressured the stock. Novo’s ziltivekimab failure at the AHA sessions added another valuation question mark for investors already watching the NAION docket.
Be careful with the headline number here. As of September 1, 2026, the federal MDL tracking shows just over 4,000 actions pending in the gastrointestinal-injury GLP-1 MDL, while the separate NAION vision-loss MDL was in the low hundreds. Those are different dockets, and they should not be conflated.
The FDA action may also affect people filing lawsuits after taking Ozempic or other GLP-1 medications and developing NAION, since a mandatory warning can strengthen plaintiffs’ arguments about what manufacturers knew and when. This is the litigation dimension that deserves more attention than the prescribing question. Settlement costs remain speculative, but the pool of potential plaintiffs is not small.
Litigation risk is not the only regulatory overhang bearing on GLP-1 valuations. The GLOBE pricing model finalized in September introduces a separate mechanism that could compress the revenue lines funding Lilly’s and Novo’s growth multiples.
How to Think About This as a Long-Term Holder
The core wealth-building question is not whether NAION is a real risk. It is whether this label change alters the fundamental demand equation for Wegovy and Zepbound. The evidence at this point says no.
What long-term holders should monitor is the litigation docket, not the label. If the NAION MDL produces large early verdicts, the calculus shifts. Until then, Monday’s market reaction was the more instructive data point: the market read this warning accurately as a compliance update, not a franchise threat.
